Navigation Links
New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir

ta showed that patient self-adjustment of insulin treatment with Levemir® was as safe and effective when compared to dosing that was adjusted by physicians according to standard-of-care. The patients who self-adjusted their dosage achieved a level of diabetes control that was comparable to that of patients receiving physician-driven adjustments. Minimal weight change was observed in both trial arms.1

The findings on weight gain are consistent with previous studies of Levemir®, the first insulin to show less weight gain versus other basal insulins in 12 of 12 controlled clinical trials*. Weight gain is a common side effect of insulin therapy, which is a concern given that 80 percent of people with type 2 diabetes are overweight or obese.

About the Study (Abstract #197-OR):
The new data presented at ADA were from a six-month analysis of 5,604 Type 2 diabetes patients, in a mainly primary care settings, and predominantly treated with Levemir® once-daily, as an add-on therapy to any other glucose-lowering regimens, or as replacement of a previous basal insulin. Patients were randomized to either the “303 Algorithm” [self adjusting their Levemir® dose every three days based on fasting plasma glucose (FPG)] or “Standard-of-Care” (Levemir® dose was physician-adjusted according to standard-of-care) treatment groups.
The study showed that the average A1c, an indicator of long-term blood glucose control, decreased from 8.5 percent at baseline to 7.9 percent at 26 weeks for the 303 Algorithm group, and from 8.5 percent to 8.0 for Standard-of-Care group (p=0.001). Compared to baseline, FPG values decreased by 34 and 21 mg/dL for 303 Algorithm and Standard-of-Care groups, respectively (p<0.0001).
At 26 weeks, 88 percent of all patients remained on once-daily Levemir® therapy. In a subset of insulin-naïve patients who added Levemir® to their standard-of-care therapy, well ove
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:6/18/2013)... 18, 2013 Apama Medical, a privately ... of next-generation atrial fibrillation technologies, today announced the ... US Patent and Trademark Office (USPTO), titled "Low ... assemblies for use on expandable structures such as ... procedures. "We are grateful to the ...
(Date:6/18/2013)... Calif. , June 18, 2013  Isis Pharmaceuticals, Inc. ... today announced that management will present a general corporate update ... Open House on Tuesday, June 25 at 2:10 p.m. Pacific ... The agenda for the meeting is as follows: 2:00 p.m. ... of record as of April 26, 2013) 2:10 p.m. – ...
(Date:6/17/2013)... , June 17, 2013 Velplex, LLC announced ... a technology platform that connects buyers and sellers of ... an industry leader. Why? It,s because ... are intimately familiar with the dental industry. They have ... and have diligently worked to negotiate some of the ...
Breaking Medicine Technology:Isis Pharmaceuticals to Present a General Corporate Update at its 2013 Annual Meeting of Stockholders and Open House 2TopProdeals.com Rises to Top as Discount Dental Supply Leader 2
(Date:6/18/2013)... Vienna, VA (PRWEB) June 18, 2013 As ... the increase in need for surgical equipment during childbirth comes ... the child from within the mother when she is unable ... difficult deliveries, they are associated with higher rates of complication ... addition to being harmful to the mother and child, forceps ...
(Date:6/18/2013)... The Drug Delivery Partnering Terms and ... the drug delivery partnering deals and agreements entered into ... report provides a detailed understanding and analysis of how ... majority of deals are discovery or development stage whereby ... to license the license drug delivery technology. These deals ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 Parker ... protecting the rights of victims injured by defective medical ... review of Medtronic’s Infuse bone graft products are now ... a medical journal, the two studies serve up two ... effectiveness” when comparing Infuse and the traditional bone graft; ...
(Date:6/18/2013)... ENT and Allergy Associates, LLP (ENTA) does not ... , New York/New Jersey’s premier ear, nose, throat, ... offering superior healthcare to children and adults in hundreds ... York area-only considers adding to its current footprint when ... the right communities to serve, the right locations from ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 Biomet ... continue to move forward in a multidistrict litigation in ... LLP reports. According to court records, the litigation’s ... at which time the Court also convened a motions ... issues pertinent to the Biomet hip replacement litigation. ...
Breaking Medicine News(10 mins):Health News:Forceps Births Double, Obesity is Major Reason in Births Complications 2Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 2Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 3Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 4Health News:Yale Releases the Findings of the Medtronic-Commissioned Infuse Bone Graft Study; Parker Waichman LLP Comments 2Health News:Yale Releases the Findings of the Medtronic-Commissioned Infuse Bone Graft Study; Parker Waichman LLP Comments 3Health News:ENT and Allergy Associates Merges with Hudson Valley ENT, Adds Five Superb Physicians, Expands Overall County Presence 2Health News:ENT and Allergy Associates Merges with Hudson Valley ENT, Adds Five Superb Physicians, Expands Overall County Presence 3Health News:ENT and Allergy Associates Merges with Hudson Valley ENT, Adds Five Superb Physicians, Expands Overall County Presence 4Health News:ENT and Allergy Associates Merges with Hudson Valley ENT, Adds Five Superb Physicians, Expands Overall County Presence 5Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 2Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 3
... between micronutrient supplementation and reduced risk of recurrence during ... June 1 issue of The Journal of Infectious Diseases, ... tuberculosis therapy, once common before the advent of anti-TB ... therapy in most low-income countries even though poor nutrition ...
... Johnson &,Johnson will participate in the Morgan Stanley ... The Ritz-Carlton in Key Biscayne,Florida. Dominic Caruso, Vice ... Company in a session scheduled at 2:20 p.m.,(Eastern ... investors and other interested parties,by accessing the Johnson ...
... that are helping doctors diagnose and treat lung ... Lung Cancer Conference jointly organized by the European ... Association for the Study of Lung Cancer (IASLC) ... No. 81O; Friday 25th April, 16:30), Israeli researchers ...
... autism are increasingly turning to sensory integration treatment ... and theyre seeing good results. In 2007, 71 ... treatment used sensory integration methods, and 91 percent ... from Temple University researchers, presented this month at ...
... (NYSE: HRC ) fiscal 2008 second quarter earnings ... invited to view its webcast the,following morning on Wednesday, ... Release: Hill-Rom Holdings, Inc.,s Fiscal 2008 Second Quarter,Earnings Release ... released to,the public after the NYSE close on Tuesday, ...
... in OTC Private Label Market, PRINCETON, N.J., ... owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced,today ... U.S. Food and Drug,Administration to manufacture and market ... Oral Solution,(Hives-Relief), 1 mg/mL (OTC). The Office of ...
Cached Medicine News:Health News:Study shows common vitamin and other micronutrient supplements reduce risks of TB recurrence 2Health News:New genetic techniques to combat lung cancer 2Health News:Autistic mannerisms reduced by sensory treatment 2Health News:Autistic mannerisms reduced by sensory treatment 3Health News:Hill-Rom Holdings, Inc. Invites You to Join Its Fiscal 2008 Second Quarter Earnings Webcast 2Health News:Ranbaxy Receives Final Approval to Manufacture and Market Cetirizine Hydrochloride Oral Solution 2
Inquire...
Inquire...
Inquire...
BD Vacutainer® Plus Plastic Serum Tubes have spray-coated silica and are used for serum determinations in chemistry, serology, and immunohematology....
Medicine Products: